PK,PD and DDI of Epaminurad and C2406 in Healthy Volunteers
NCT ID: NCT06665425
Last Updated: 2025-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
18 participants
INTERVENTIONAL
2025-03-24
2025-09-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy
NCT01236456
Dimethyl Fumarate in Adrenomyeloneuropathy
NCT06513533
To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy
NCT06940336
A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects
NCT01644240
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
NCT02562066
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Epaminurad 9mg, C2406 0.6mg
Epaminurad 9 mg
Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
C2406
Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Epaminurad 9 mg
Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
C2406
Period 1: Epaminurad / Period 2: C2406 -\> Epaminurad + C2406
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Weight: between 50.0 kg\~90.0 kg, Body Mass Index(BMI): 18.0 kg/m\^2 or heavier and below 30.0 kg/m\^2
Exclusion Criteria
2. Clinical examination
* eGFR (CKD-EPI) \< 90mL/min/1.73m\^2
* Serum uric acid \< 3 mg/dL or \> 7 mg/dL
* AST (SGOT), ALT (SGPT) \> upper limit of normal ranges X 1.5
* Total bilirubin, γ-GTP \> upper limit of normal ranges X 1.5
* CK \> upper limit of normal ranges X 2
* Positive serologic results
19 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
JW Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kyung-sang Yu, MD
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital Clinical Trials Center
Seoul, Seoul, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JW24103
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.